BPC-157 muscle research: the rat crush and transection studies
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Not approved. BPC-157 is not FDA-approved for any use and appears on WADA's prohibited list. See our legal status file and anti-doping explainer.
Online discussion of BPC-157 and muscle tends to cite "studies" without naming them. When the papers are traced, the skeletal-muscle literature turns out to be a small set of rat experiments in which a leg muscle was deliberately crushed or cut, then examined over the following weeks. This explainer describes what those experiments did, what they measured, who ran them, and what has never been tested. It reports findings as the authors described them. It does not suggest that the results apply to people.
Who produced the muscle papers
BPC-157 is a synthetic 15-amino-acid peptide described as derived from a protein in gastric juice. Its research history is unusually concentrated. Most of the preclinical work, including the muscle papers below, comes from one research group at the University of Zagreb in Croatia. The same group wrote a 2021 review of the compound's wound-healing literature [2]. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found a literature dominated by preclinical studies, with only one clinical study among those it included [1].
Concentration in one lab is not proof of error. It does mean the findings have not been tested by independent groups using their own methods, animals and outcome assessors, and independent replication is one of the basic checks in experimental science. Our history page traces how the research programme began.
Model 1: quadriceps transection in the rat
The best-known muscle paper is a 2006 study in the Journal of Orthopaedic Research titled "Effective therapy of transected quadriceps muscle in rat" [3]. In this model the quadriceps, the large muscle at the front of the thigh, is surgically cut across in anaesthetised rats. That creates a severe, standardised injury whose aftermath can be followed over time.
The paper compared animals that received BPC-157 with control animals. As described in the abstract, the outcomes fell into four kinds:
Macroscopic assessment: what the injured muscle looked like to the eye at set time points, such as the gap between the cut ends.
Microscopic (histological) assessment: tissue sections examined under a microscope for the organisation of muscle fibres and connective tissue.
Functional assessment: measures of how the animals used the affected limb.
Biomechanical assessment: mechanical testing of the repaired tissue, such as the load it could bear before failing.
The authors reported more favourable results in the BPC-157 group than in controls across these measures [3]. Their title uses the word "therapy". That is the authors' wording about a rat model. It is not a regulatory finding and not evidence about humans.
Model 2: gastrocnemius crush injury in the rat
A 2008 paper in Surgery Today used a different injury: a crush of the gastrocnemius complex, the main calf muscle group in the rat [4]. Crush injuries differ from cuts. The muscle stays in one piece, but fibres and small blood vessels are damaged across the crushed area, a pattern often used to model blunt trauma.
The study again compared BPC-157 and control groups and reported functional, macroscopic, microscopic and biomechanical outcomes over the follow-up period. The authors described the results as favourable to BPC-157 [4]. As with the transection study, the paper's authors belong to the Zagreb group.
What these readouts can and cannot tell us
Each type of readout has known limits:
Histology depends on which sections are sampled and who scores them. Whether scoring was blinded to group assignment matters a great deal, and abstracts rarely make it clear.
Functional scores in rodents capture gait or limb use. They do not measure strength or performance in any human sense.
Biomechanical load-to-failure tests measure tissue mechanics at one time point in an acute surgical injury. They say nothing about long-term outcomes or rare harms.
Group sizes in this kind of rat experiment are typically small, so effect estimates can be unstable.
There are also larger gaps. Rats regenerate muscle tissue on a different timescale from humans. A surgical cut or controlled crush is not the same as the strains and overuse injuries discussed in sport. Neither paper was designed to look for long-term safety signals. Our explainer on what rodent models can and cannot show covers these limits in more depth, and the study evaluation checklist gives a structured way to read any single paper.
Tendon research raises the same questions, because the injuries sit side by side in the limb and come from the same lab. See BPC-157 tendon research for those models.
Zero controlled human muscle trials
No controlled clinical trial of BPC-157 for skeletal-muscle injury in humans has been published. The human literature on BPC-157 is very small:
A 2021 retrospective report described people with various types of knee pain. It had no control group and did not study muscle injury [6].
A 2025 pilot study looked at safety in a very small number of adults. It was not designed to measure any effect on muscle [7].
A 2026 systematic review of human evidence in orthopaedic and regenerative medicine assessed both efficacy and safety data across the available human reports [5].
Recent reviews in orthopaedics and sports medicine describe the same gap between a large animal literature and minimal human data. They cover therapeutic peptides in orthopaedics [9], injectable peptides in regenerative and sports medicine [10], and approved versus unapproved peptides for musculoskeletal injuries [8]. None of these reviews identifies a controlled human muscle trial, because none exists in the published record.
Regulators have reached their own conclusions. FDA lists BPC-157 among bulk drug substances nominated for compounding that may present significant safety risks [11]. WADA's prohibited list governs its status in sport [12]. Our evidence guide brings the claims and the gaps together in one place.
How this page was put together
We cite only papers we can link to, describe the model and outcomes as the authors reported them, and avoid extrapolating to people. The About page explains our sourcing rules and how the site is funded.
Further reading on appraising animal research
Readers who want to judge laboratory studies for themselves often find that a good methods book is worth more than any single summary. Useful titles explain randomisation, blinding of outcome assessors, sample-size reasoning and publication bias, using worked examples from real papers.
When comparing books on research methods or evidence appraisal, these criteria are worth checking:
Scope: whether it covers animal and laboratory studies, not only human trials.
Author background: methodologists or statisticians with a record of published work in the field.
Edition date: recent editions tend to cover reporting guidelines and replication concerns.
Format: worked examples and checklists suit self-study; denser textbooks suit structured courses.
Price transparency: the print, e-book and used prices are clear before purchase.
A short, practical guide to critical appraisal is usually the best first purchase. A full statistics textbook can come later for readers who want to go further.
Any book we list is chosen on the criteria above. Commission has no effect on which titles appear.
Library copies and older editions often cover the same core methods at lower cost.
Frequently asked questions
Has BPC-157 been tested on human skeletal muscle?
No controlled human trial of BPC-157 for skeletal-muscle injury has been published. The few human reports are small and uncontrolled, and none studied muscle injury [6][7]. A 2026 systematic review assessed the available human data [5].
What muscle injuries did the rat studies use?
One study surgically cut the quadriceps muscle across [3], and another crushed the gastrocnemius complex in the calf [4]. Both compared BPC-157 groups with controls and reported macroscopic, microscopic, functional and biomechanical outcomes.
Why does it matter that one lab produced most of the studies?
Independent replication tests whether a result holds up under different hands, animals and assessors. Without it, lab-specific methods or unblinded scoring can shape findings in ways readers cannot detect [1].
Is BPC-157 allowed in sport?
It is listed on WADA's prohibited list, so it is banned for athletes covered by the anti-doping code [12]. Details are in our anti-doping explainer.
Related on this site
BPC-157 animal studies: what rodent models can and cannot show
How to evaluate a BPC-157 study: a reader's checklist and reading list
Is BPC-157 banned in sport? WADA's prohibited list, explained
Last updated: 23 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.
Sources
Read next
How to evaluate a BPC-157 study: a reader's checklist and reading list
A five-question checklist for reading BPC-157 studies, applied to the three human reports and two systematic reviews, plus a labelled reading list on evidence appraisal.
Sports wearables buyer's guide: GPS watches, chest straps, trackers
How to compare wearables for athletes: what GPS watches, chest straps and activity trackers measure, which figures are estimates, and how to weigh battery, data export, privacy and price.
BPC-157 vs TB-500: the evidence and regulatory records compared
Two peptides, one thin record. How BPC-157 and TB-500 compare on human evidence, FDA's July 2026 compounding review and WADA's Prohibited List, with every unverified claim flagged.